NCT05963334

A Non-randomized Control Study Comparing Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer

Extracted Fields (from Registry)
Protocol IDNCT05963334
Registration Date2023-07-27
Statuscompleted
SponsorCairo University
CountryEgypt
Industrynot industry
Blindingunblinded
Center Typesingel-center RCT
Scopenational RCT
First Patient In2015-01-01
Last Patient Out2023-06-06
Publicationn
Gender %FEMALE
Mean Age18 Years -
LLM Classifications (Side-by-Side)
Field GLM
glm-5.1
6446ms / 10009 tok 		CLAUDE
claude-sonnet-4-20250514
Thinking: claude-opus-4-20250514
5259ms / 11470 tok 		OPENAI
gpt-4o
Thinking: o3
3309ms / 9813 tok 		Review
rct_type N/A N/A N/A OK
cancer_status Cancer Cancer Cancer OK
non_cancer_spec N/A N/A N/A OK
setting_patient outpatient outpatient outpatient OK
setting_place other other other OK
feasibility N/A N/A → N/A
shaky reasoning
✓ Unanimous Initial: N/A Requery: N/A — The study design is a non-randomized interventional study rather than a randomized controlled trial.
 N/A fully powered RCT → N/A
shaky reasoning
✓ Unanimous Initial: fully powered RCT Requery: N/A — This is explicitly described as a non-randomized control study, making it an observational study rather than an RCT.
 N/A fully powered RCT → N/A
shaky reasoning
✓ Unanimous Initial: fully powered RCT Requery: N/A — This is a non-randomized control study, not an RCT.
 OK
intervention_pharmacologic yes yes yes OK
intervention_chemo_immuno_radio yes yes yes OK
intervention_complementary no no no OK
intervention_device no no no OK
intervention_psychological no no no OK
intervention_complex no no no OK
intervention_acp no no no OK
intervention_music no no no OK
intervention_screening no no no OK
intervention_palliative no no no OK
intervention_education no no no OK
intervention_digital no no no OK
intervention_other no no no OK
outcome_symptom no yes → no
shaky reasoning
✓ Unanimous Initial: yes Requery: no — The study measures laboratory parameters and uses quality of life instruments (FACT-O and FACT-GOG-NTX), which fall under QoL assessment rather than symptom-specific measurement tools.
 no no → yes → no
shaky reasoning
✓ Unanimous Initial: no Requery: yes — The study measures neurotoxicity symptoms using FACT/GOG-NTX (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group neurotoxicity), which is a validated symptom assessment scale for treatment-related neurological symptoms. Thinking: no — The trial measures lab values/biomarkers and quality of life using FACT scales, but does not include any validated symptom measurement instruments as outcomes.
 no no → no → no
shaky reasoning
✓ Unanimous Initial: no Requery: no — The trial does not measure specific symptoms using validated instruments but focuses on laboratory parameters, quality of life using FACT questionnaires, and biomarkers not directly related to symptom assessment. Thinking: no — Outcomes include laboratory toxicity markers and FACT quality-of-life questionnaires but no validated symptom instruments such as pain, fatigue, or mood scales.
 OK
outcome_qol yes yes yes OK
outcome_dignity no no no OK
outcome_cost no no no OK
outcome_other no yes → no
shaky reasoning
✓ Unanimous Initial: yes Requery: no — All primary outcomes (routine laboratory parameters, kidney/anemia biomarkers, and quality of life) fall under the categories of symptoms, quality of life, and costs.
 no yes → no
shaky reasoning
✓ Unanimous Initial: yes Requery: no — All primary outcomes focus on laboratory parameters for safety/toxicity assessment and quality of life measures, which fall within the symptom/QoL categories.
 no no → no
shaky reasoning
✓ Unanimous Initial: no Requery: no — All outcomes focus on symptoms, QoL, and safety, which are related to toxicity and life quality measurements, with no mention of other distinct outcomes like caregiver outcomes or advance directive completion.
 OK
pharmacologic_sub chemotherapy chemotherapy chemotherapy OK
Back to Studies